Table 4 Progression-Free Survival in Pazopanib Recipients by Dose Modifications (ITT Population)
Dose Modifications | n (%) | mPFS, weeks (95% CI) |
|---|---|---|
Dose reductions | ||
No dose reduction | 154 (100) | 11.9 (8.9–19.3) |
Progressed or Died | 104 (68) | |
≥ 1 dose reductions | 92 (100) | 27.7 (21.1–35.7) |
Progressed or Died | 59 (64) | |
1 dose reduction | 54 (100) | 27.1 (20.1–35.7) |
Progressed or Died | 29 (54) | |
2 or more dose reductions | 38 (100) | 28.1 (20.1–38.1) |
Progressed or Died | 30 (79) | |
Dose interruptions | ||
No dose interruption | 107 (100) | 11.0 (8.1–19.3) |
Progressed or Died | 71 (66) | |
≥ 1 dose interruptions | 139 (100) | 21.3 (20.1–27.7) |
Progressed or Died | 92 (66) | |
1 dose interruption | 69 (100) | 20.0 (12.4–21.3) |
Progressed or Died | 45 (65) | |
2 or more dose interruptions | 70 (100) | 27.7 (21.0–35.6) |
Progressed or Died | 47 (67) | |